Cite
HARVARD Citation
Garralda, E. et al. (n.d.). 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. Journal for immunotherapy of cancer. pp. A250-A251. [Online].